Zai Lab Limited (ZLAB +21.1%) is up in early trade in response to positive results from a late-stage study evaluating MacroGenics’ margetuximab in certain breast cancer patients.
Shanghai-base Zai Lab owns development and commercialization rights to the monoclonal antibody (plus two other programs) in China, Hong Kong, Macau and Taiwan under a November 2018 agreement with MGNX.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.